Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.48 Million CAD | -32.75% |
| 2022 | 11.12 Million CAD | 0.73% |
| 2021 | 11.04 Million CAD | 136.95% |
| 2020 | 4.66 Million CAD | -28.81% |
| 2019 | 6.54 Million CAD | 21.94% |
| 2018 | 5.36 Million CAD | 11.58% |
| 2017 | 4.81 Million CAD | -3.37% |
| 2016 | 4.98 Million CAD | -14.72% |
| 2015 | 5.83 Million CAD | 29.44% |
| 2014 | 4.51 Million CAD | 17.67% |
| 2013 | 3.83 Million CAD | 39.18% |
| 2012 | 2.75 Million CAD | -7.7% |
| 2011 | 2.98 Million CAD | -20.08% |
| 2010 | 3.73 Million CAD | 4.77% |
| 2009 | 3.56 Million CAD | 41.75% |
| 2008 | 2.51 Million CAD | 30.1% |
| 2007 | 1.93 Million CAD | 2.12% |
| 2006 | 1.89 Million CAD | -29.93% |
| 2005 | 2.7 Million CAD | 4.83% |
| 2004 | 2.57 Million CAD | 41.37% |
| 2003 | 1.82 Million CAD | -7.53% |
| 2002 | 1.97 Million CAD | -3.31% |
| 2001 | 2.03 Million CAD | 59.38% |
| 2000 | 1.27 Million CAD | 27.92% |
| 1999 | 1 Million CAD | -60.0% |
| 1998 | 2.5 Million CAD | 13.64% |
| 1997 | 2.2 Million CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 2.74 Million CAD | -7.5% |
| 2024 Q1 | 6.22 Million CAD | 336.6% |
| 2024 Q2 | 2.97 Million CAD | -52.25% |
| 2023 Q2 | 2.52 Million CAD | 113.1% |
| 2023 FY | 7.48 Million CAD | -32.75% |
| 2023 Q4 | 1.42 Million CAD | -39.17% |
| 2023 Q3 | 2.34 Million CAD | -7.3% |
| 2023 Q1 | 1.18 Million CAD | -41.3% |
| 2022 Q3 | 2.76 Million CAD | -11.24% |
| 2022 Q4 | 2.02 Million CAD | -26.95% |
| 2022 FY | 11.12 Million CAD | 0.73% |
| 2022 Q1 | 3.22 Million CAD | -0.74% |
| 2022 Q2 | 3.11 Million CAD | -3.28% |
| 2021 Q3 | 3.44 Million CAD | 32.27% |
| 2021 FY | 11.04 Million CAD | 136.95% |
| 2021 Q1 | 1.74 Million CAD | 85.69% |
| 2021 Q2 | 2.6 Million CAD | 49.09% |
| 2021 Q4 | 3.24 Million CAD | -5.81% |
| 2020 Q3 | 1.35 Million CAD | 2.65% |
| 2020 Q2 | 1.32 Million CAD | 26.53% |
| 2020 FY | 4.66 Million CAD | -28.81% |
| 2020 Q4 | 940.95 Thousand CAD | -30.59% |
| 2020 Q1 | 1.04 Million CAD | -33.78% |
| 2019 Q1 | 1.29 Million CAD | -6.1% |
| 2019 Q4 | 1.57 Million CAD | 3.74% |
| 2019 Q3 | 1.51 Million CAD | -29.71% |
| 2019 Q2 | 2.16 Million CAD | 67.49% |
| 2019 FY | 6.54 Million CAD | 21.94% |
| 2018 Q4 | 1.37 Million CAD | -9.79% |
| 2018 Q2 | 1.15 Million CAD | -12.62% |
| 2018 FY | 5.36 Million CAD | 11.58% |
| 2018 Q1 | 1.31 Million CAD | 21.56% |
| 2018 Q3 | 1.52 Million CAD | 32.19% |
| 2017 Q4 | 1.08 Million CAD | -27.56% |
| 2017 FY | 4.81 Million CAD | -3.37% |
| 2017 Q3 | 1.49 Million CAD | 5.85% |
| 2017 Q2 | 1.41 Million CAD | 73.72% |
| 2017 Q1 | 814.52 Thousand CAD | -61.81% |
| 2016 Q2 | 1.33 Million CAD | 272.96% |
| 2016 FY | 4.98 Million CAD | -14.72% |
| 2016 Q1 | 357.45 Thousand CAD | -83.01% |
| 2016 Q3 | 1.15 Million CAD | -13.23% |
| 2016 Q4 | 2.13 Million CAD | 84.34% |
| 2015 Q3 | 1.25 Million CAD | -5.63% |
| 2015 FY | 5.83 Million CAD | 29.44% |
| 2015 Q2 | 1.33 Million CAD | 17.96% |
| 2015 Q1 | 1.12 Million CAD | -2.9% |
| 2015 Q4 | 2.1 Million CAD | 67.5% |
| 2014 Q4 | 1.16 Million CAD | 0.98% |
| 2014 Q3 | 1.15 Million CAD | 5.0% |
| 2014 Q1 | 1.1 Million CAD | -21.34% |
| 2014 Q2 | 1.09 Million CAD | -0.67% |
| 2014 FY | 4.51 Million CAD | 17.67% |
| 2013 FY | 3.83 Million CAD | 39.18% |
| 2013 Q2 | 1.01 Million CAD | 148.74% |
| 2013 Q1 | 409.61 Thousand CAD | -13.24% |
| 2013 Q3 | 924.56 Thousand CAD | -9.26% |
| 2013 Q4 | 1.4 Million CAD | 51.68% |
| 2012 Q1 | 641.78 Thousand CAD | -18.64% |
| 2012 FY | 2.75 Million CAD | -7.7% |
| 2012 Q2 | 963.67 Thousand CAD | 50.15% |
| 2012 Q4 | 472.11 Thousand CAD | -76.11% |
| 2012 Q3 | 1.97 Million CAD | 105.03% |
| 2011 Q3 | 727.83 Thousand CAD | -29.75% |
| 2011 Q4 | 788.86 Thousand CAD | 8.39% |
| 2011 FY | 2.98 Million CAD | -20.08% |
| 2011 Q1 | 431.93 Thousand CAD | -66.72% |
| 2011 Q2 | 1.03 Million CAD | 139.87% |
| 2010 Q1 | 707.13 Thousand CAD | -24.75% |
| 2010 Q3 | 625.58 Thousand CAD | -43.33% |
| 2010 Q2 | 1.1 Million CAD | 56.12% |
| 2010 FY | 3.73 Million CAD | 4.77% |
| 2010 Q4 | 1.29 Million CAD | 107.49% |
| 2009 Q3 | 738.47 Thousand CAD | -20.6% |
| 2009 Q4 | 939.67 Thousand CAD | 27.24% |
| 2009 FY | 3.56 Million CAD | 41.75% |
| 2009 Q2 | 930.12 Thousand CAD | -2.74% |
| 2009 Q1 | 956.3 Thousand CAD | 53.53% |
| 2008 FY | 2.51 Million CAD | 30.1% |
| 2008 Q4 | 622.86 Thousand CAD | -24.88% |
| 2008 Q1 | 502.76 Thousand CAD | 41.6% |
| 2008 Q2 | 559.92 Thousand CAD | 11.37% |
| 2008 Q3 | 829.18 Thousand CAD | 48.09% |
| 2007 Q4 | 355.04 Thousand CAD | -38.98% |
| 2007 FY | 1.93 Million CAD | 2.12% |
| 2007 Q3 | 581.83 Thousand CAD | -10.13% |
| 2007 Q2 | 647.41 Thousand CAD | 85.68% |
| 2007 Q1 | 348.67 Thousand CAD | 55.23% |
| 2006 FY | 1.89 Million CAD | -29.93% |
| 2006 Q1 | 658.03 Thousand CAD | 29.28% |
| 2006 Q4 | 224.62 Thousand CAD | -55.21% |
| 2006 Q2 | 508.65 Thousand CAD | -22.7% |
| 2006 Q3 | 501.51 Thousand CAD | -1.4% |
| 2005 Q2 | 614.87 Thousand CAD | -20.78% |
| 2005 Q1 | 776.13 Thousand CAD | -36.84% |
| 2005 Q3 | 801.42 Thousand CAD | 30.34% |
| 2005 Q4 | 508.99 Thousand CAD | -36.49% |
| 2005 FY | 2.7 Million CAD | 4.83% |
| 2004 Q3 | 416.73 Thousand CAD | -11.08% |
| 2004 Q1 | 462.61 Thousand CAD | -27.21% |
| 2004 Q2 | 468.66 Thousand CAD | 1.31% |
| 2004 FY | 2.57 Million CAD | 41.37% |
| 2004 Q4 | 1.22 Million CAD | 194.89% |
| 2003 Q3 | 330.41 Thousand CAD | -28.89% |
| 2003 Q2 | 464.69 Thousand CAD | 18.5% |
| 2003 Q1 | 392.15 Thousand CAD | -22.38% |
| 2003 Q4 | 635.52 Thousand CAD | 92.34% |
| 2003 FY | 1.82 Million CAD | -7.53% |
| 2002 Q3 | 652.41 Thousand CAD | 21.55% |
| 2002 FY | 1.97 Million CAD | -3.31% |
| 2002 Q2 | 536.74 Thousand CAD | 93.79% |
| 2002 Q1 | 276.97 Thousand CAD | -33.67% |
| 2002 Q4 | 505.19 Thousand CAD | -22.57% |
| 2001 Q2 | 540.78 Thousand CAD | -6.75% |
| 2001 Q4 | 417.58 Thousand CAD | -17.21% |
| 2001 Q3 | 504.39 Thousand CAD | -6.73% |
| 2001 Q1 | 579.93 Thousand CAD | 52.92% |
| 2001 FY | 2.03 Million CAD | 59.38% |
| 2000 Q4 | 379.24 Thousand CAD | 26.42% |
| 2000 Q3 | 300 Thousand CAD | 0.0% |
| 2000 Q2 | 300 Thousand CAD | 0.0% |
| 2000 Q1 | 300 Thousand CAD | 0.0% |
| 2000 FY | 1.27 Million CAD | 27.92% |
| 1999 Q3 | 400 Thousand CAD | 300.0% |
| 1999 Q4 | 300 Thousand CAD | -25.0% |
| 1999 Q1 | 300 Thousand CAD | 200.0% |
| 1999 Q2 | 100 Thousand CAD | -66.67% |
| 1999 FY | 1 Million CAD | -60.0% |
| 1998 Q1 | 300 Thousand CAD | -25.0% |
| 1998 FY | 2.5 Million CAD | 13.64% |
| 1998 Q4 | 100 Thousand CAD | -92.31% |
| 1998 Q3 | 1.3 Million CAD | 62.5% |
| 1998 Q2 | 800 Thousand CAD | 166.67% |
| 1997 FY | 2.2 Million CAD | 0.0% |
| 1997 Q3 | 800 Thousand CAD | 60.0% |
| 1997 Q2 | 500 Thousand CAD | 0.0% |
| 1997 Q4 | 400 Thousand CAD | -50.0% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ContraFect Corporation | -154 Thousand USD | 4958.009% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 50.121% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -241077.756% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 23.613% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -11282.263% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 36.09% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 93.719% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 22007.274% |
| Marizyme, Inc. | 457.7 Thousand USD | -1534.543% |
| Genus plc | 178.7 Million USD | 95.813% |
| Pharming Group N.V. | 220.1 Million USD | 96.601% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -11922.843% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1723.982% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 68112.127% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -9646.27% |
| IMV Inc. | -962.29 Thousand USD | 877.445% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 2030.662% |
| ONE Bio Corp. | 20.12 Million USD | 62.826% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 81.42% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 48604.499% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 83.134% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -10587.62% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 6121.146% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Mesoblast Limited | -35.16 Million USD | 121.273% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 151177.019% |
| Arch Therapeutics, Inc. | -2439.00 USD | 306837.761% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -5224.793% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 7771.983% |
| GB Sciences, Inc. | -624.00 USD | 1199031.731% |
| MultiCell Technologies, Inc. | 49.32 USD | -15168865.937% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 8796.394% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.901% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 3596895.192% |
| Enzolytics Inc. | 30.7 Thousand USD | -24262.818% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -1450.751% |
| argenx SE | 1.1 Billion USD | 99.325% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 73.522% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 90399.747% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 84577.575% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 9022.389% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.173% |
| Kadimastem Ltd | -630.13 Thousand USD | 1287.253% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -657.235% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 755.354% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 22.159% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 15062.668% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -15199.252% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | -8988.00 USD | 83336.916% |
| LadRx Corporation | -11.83 Thousand USD | 63313.638% |
| Cell Source, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 15602.464% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4137.276% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 129.0% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 1554.07% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1111.78% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 51.498% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -1562.36% |
| SYBLEU INC | 11.69 Thousand USD | -63864.894% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 2441.524% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4137.276% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -451.256% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -62.355% |
| CytoDyn Inc. | -29 Thousand USD | 25897.703% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 2105.72% |
| Neutra Corp. | 14.33 Thousand USD | -52089.285% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 9223.578% |
| PureTech Health plc | -1.6 Million USD | 566.708% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 847.21% |
| IXICO plc | 3.27 Million USD | -128.787% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 1178.002% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 517.718% |
| CSL Limited | 7.7 Billion USD | 99.903% |
| Cellectis S.A. | 18 Thousand USD | -41462.967% |